Navigation Links
Biologics Research Promises to Bolster Future of Medicine
Date:3/11/2013

WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

The report includes biologics in human clinical trials or under review by the U.S. Food and Drug Administration such as:

  • 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma;
  • 134 vaccines for infectious diseases;
  • 71 medicines for autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis;
  • 58 treatments for cardiovascular disease.

"These medicines reflect the cutting-edge research being conducted across the country by biopharmaceutical companies in order to provide new treatment options to patients," stated PhRMA President and CEO John J. Castellani .

The biologic medicines now in development make use of a range of new technologies to harness scientific progress.  Among the biologic medicines in development are:

  • A genetically-modified virus-based vaccine to treat melanoma;
  • A monoclonal antibody for the treatment of asthma;
  • An antisense therapy for the treatment of leukemia;
  • A recombinant fusion protein to treat type 2 diabetes.

"In order to realize the full potential of novel biologics to improve human health, it is essential to maintain public policy and regulatory environments to support the research and development that drives biomedical innovation," concluded Castellani.

The U.S. biopharmaceutical research sector supports nearly four million jobs across the economy, invests billions of dollars in research and development each year, and accounts for nearly 20 percent of all domestic R&D funded by U.S. businesses generating high-quality, high-wage jobs, powering the U.S. economy, and developing critical new treatments against our most costly and challenging diseases. 

The Biologic Medicines in Development report as well as an overview and other supplementary materials are available on PhRMA's website at http://phrma.org/research/new-medicines.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org 
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org   
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
2. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
3. Employers Becoming Savvier About Biologics and Specialty Drugs
4. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
5. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
6. Pinnacle Biologics acquires PDT laser technology
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
9. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
10. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
11. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):